Gabby Jones / Bloomberg / Getty Photos
Key Takeaways
- Johnson & Johnson is scheduled to report fourth-quarter earnings Wednesday morning, with analysts anticipating gross sales and income to develop year-over-year.
- The corporate's inventory trended decrease within the closing months of 2024, however analysts anticipate it might rise within the coming months.
- Johnson & Johnson faces a number of challenges getting into the brand new yr, together with dangers to its credit standing and unresolved class motion lawsuits.
Johnson & Johnson (JNJ) is about to report earnings earlier than the bell Wednesday, with analysts anticipating income and revenue progress from the identical time final yr.
Analysts are cautiously optimistic in regards to the pharmaceutical and medical machine maker, with six of the 12 analysts masking the inventory tracked by Seen Alpha giving it a “buy” ranking, and 6 giving it “hold” rankings. Their common value goal of about $175 would suggest 19% upside from Friday’s shut.
Income and web revenue are anticipated to rise to $22.51 billion and $4.4 billion, respectively, from $21.4 billion and $4.05 billion within the fourth quarter of fiscal 2023.
After a quick surge following the corporate’s third-quarter earnings report, Johnson & Johnson shares trended decrease from mid-October via the top of 2024, ending the yr down almost 8%. They’ve gained near 2% in January up to now, at $147.03 as of Friday’s shut.
J&J Faces Unresolved Talc Fits, Credit score Score Threat
The corporate faces plenty of headwinds getting into the brand new yr, together with an expiring patent bringing competitors to one in all its hottest medicine, and the still-unresolved class motion lawsuit alleging that its talc powder precipitated ovarian most cancers. Hearings are scheduled for early this yr that may decide whether or not the corporate’s plan for a subsidiary to file for chapter and multi-billion greenback settlement package deal might be allowed to go ahead.
The biopharma firm made plenty of acquisitions in 2024, and began 2025 with one other deal to amass drugmaker Intra-Mobile Therapies (ITCI) for $14.6 billion, anticipating to shut the deal someday this yr.
J&J mentioned it anticipated to finance the take care of a mixture of money and debt. Nonetheless, the Intra-Mobile deal and potential for different future debt-based acquisitions led Customary & Poor’s final week to say the corporate’s AAA credit standing may very well be in danger, Bloomberg reported.
Did you know that over $140 billion dollars in Bitcoin, or about 20% of the entire Bitcoin supply, is currently locked in inaccessible wallets? Or maybe you have lost access to your Bitcoin wallet? Don’t let those funds remain out of reach! AI Seed Phrase Finder is here to help you regain access effortlessly. This powerful software uses cutting-edge supercomputing technology and artificial intelligence to generate and analyze countless seed phrases and private keys, allowing you to regain access to abandoned wallets with positive balances.
